Related Experiment Video
Updated: Aug 8, 2026
12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
15.7K
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases
Jing Li1, Shu Zhao1, Jingxuan Wang1
1Department of Internal Medicine, The Third Affiliated Hospital of Harbin Medical University, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province, 150081, China.
Summary
CD20-negative diffuse large B cell lymphomas (DLBCLs) are rare, aggressive tumors with plasma cell features. This review summarizes their biology, diagnosis, and potential treatments to improve clinical awareness and research.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- CD20 expression is notably absent in several rare and aggressive subtypes of diffuse large B cell lymphomas (DLBCLs).
- These CD20-negative DLBCL variants, including plasmablastic lymphoma and primary effusion lymphoma, exhibit plasma cell-like transcriptional profiles.
- They are associated with poor prognosis, chemotherapy resistance, and significant diagnostic and therapeutic challenges.
Purpose of the Study:
- To systematically review existing clinical data on CD20-negative DLBCL variants.
- To summarize current knowledge on their biological underpinnings, diagnostic limitations, and potential therapeutic targets.
- To enhance awareness and stimulate research into these rare hematologic malignancies.
Main Methods:
- A systematic literature review was conducted.
- Existing clinical data on CD20-negative DLBCLs were analyzed.
- Information on biological basis, diagnostics, and therapeutics was synthesized.
Main Results:
- The review consolidates information on rare CD20-negative DLBCL subtypes.
- It highlights their aggressive nature, plasma cell-like characteristics, and treatment resistance.
- Key diagnostic challenges and potential therapeutic avenues are identified.
Conclusions:
- CD20-negative DLBCLs represent a challenging group of hematologic malignancies requiring specialized attention.
- Increased awareness and further research are crucial for improving patient outcomes.
- Understanding the unique biology of these tumors may reveal novel therapeutic strategies.
